Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib vs Chemotherapy in Pretreated ALK+ NSCLC (ALUR)
NCT02604342Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2015
- Primary completion
- Jan 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 15
01
Overview
A Phase 3 trial of alectinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Nov 2015; status: completed.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02604342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02604342.